Carlos Campoy
Net Worth
Last updated:
What is Carlos Campoy net worth?
The estimated net worth of Mr. Carlos Campoy is at least $2,391,867 as of 16 Mar 2023. He owns shares worth $76,452 as insider, has earned $9,075 from insider trading and has received compensation worth at least $2,306,340 in CytomX Therapeutics, Inc..
What is the salary of Carlos Campoy?
Mr. Carlos Campoy salary is $768,780 per year as Senior Vice President & Chief Financial Officer in CytomX Therapeutics, Inc..
How old is Carlos Campoy?
Mr. Carlos Campoy is 60 years old, born in 1965.
What stocks does Carlos Campoy currently own?
As insider, Mr. Carlos Campoy owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | Senior Vice President & Chief Financial Officer | 38,224 | $2 | $76,452 |
What does CytomX Therapeutics, Inc. do?
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Carlos Campoy insider trading
CytomX Therapeutics, Inc.
Mr. Carlos Campoy has made 2 insider trades between 2022-2023, according to the Form 4 filled with the SEC. Most recently he sold 1,748 units of CTMX stock worth $3,459 on 16 Mar 2023.
The largest trade he's ever made was exercising 3,949 units of CTMX stock on 20 Jul 2022. As of 16 Mar 2023 he still owns at least 38,224 units of CTMX stock.
CytomX Therapeutics key executives
CytomX Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Alison L. Hannah M.D. (64) Senior Vice President & Chief Medical Officer
- Dr. Amy C. Peterson M.D. (58) Executive Vice President & Chief Devel. Officer
- Dr. Sean A. McCarthy D.Phil., DPHIL (58) Chairman, Chief Executive Officer & Pres
- Mr. Carlos Campoy (60) Senior Vice President & Chief Financial Officer
- Mr. Frederick W. Gluck (90) Co-Founder & Independent Director
- Mr. Lloyd A. Rowland Jr., J.D. (68) Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec.